Supplemental Material to:

Yang P-M, Lin P-J, Chen C-C
CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1
Epigenetics 2012; 7(4); http://dx.doi.org/10.4161/epi.7.4.19373

http://www.landesbioscience.com/journals/epigenetics/article/19373/

Included: Figures S1 and S2, Table S1

Legends to supplementary figures

Suppl. Fig. S1. TSA-induced CD1d mRNA expression was not affected by various inhibitors in A549 and TC-1 cells. A549 and TC-1 cells were pretreated with Ro318220 (1 μM), Y27632 (30 μM), KN-62 (5 μM), SB203580 (30 μM), PD98059 (30 μM), SP600125 (25 μM), LY294002 (30 μM), rapamycin (100 ng/ml), SH-5 (20 μM), or wortmannin (0.3 μM) for 1 hour, then treated with TSA (1 μM) overnight. Total RNA (2 μg) were used for RT-PCR.

Suppl. Fig. S2. Effects of apicidin alone or combination with MS-275 on CD1d mRNA expression in A549 cells. A549 cells were treated with 0.5, 1, or 2 μM apicidin in the presence or absence of 1 μM MS-275 for 24 h. Total RNA (2 μg) were used for RT-PCR.


A549
TSA
Basal
–
Ro318220
Y27632
KN-62
SB203580
PD98059
SP600125
LY294002
rapamycin
SH-5
Wortmannin
CD1d
Actin
TC-1
TSA
Basal
–
Ro318220
Y27632
KN-62
SB203580
PD98059
SP600125
LY294002
rapamycin
SH-5
Wortmannin
CD1d
GAPDH

suppl. Fig. S1



suppl. Fig. S2

Suppl. Table S1. Comparison of the IC50 values of HDAC inhibitors reported in the literatures.

Compound	HDAC inhibition	IC50 (nM) reported in the literates						Ranges of IC50 (nM)
		Ref. 1	Ref. 2	Ref. 3	Ref. 4	Ref. 5	Ref. 6	
TSA	HDAC1	100	1	1.5		2		1-2; 100
	HDAC2					3		3
	HDAC3	300		0.6		4		0.6-4; 300
SAHA	HDAC1		148	119	21	68	100	21-148
	HDAC2					164	440	164-440
	HDAC3		119	106	37	48	20	20-119
MS-275	HDAC1	300	5990	185	180	181	13000	180-300; >5990
	HDAC2					1155	510	510-1155
	HDAC3	8000		201	740	2311	70	70-740; >2311
Apicidin	HDAC1			2		>10000	<10	<10; >10000
	HDAC2					120	33.7	33.7-120
	HDAC3			0.7		43	<10	0.7-43

References

1. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307:720-8.
2. Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, et al. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci 2004; 74:2693-705.
3. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A 2004; 101:15064-9.
4. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121:1138-48.
5. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409:581-9.
6. Blackwell L, Norris J, Suto CM, Janzen WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 2008; 82:1050-8.